The TTI-109 Phase 1 data validates the prodrug strategy with improved tolerability, preserved PK, and clear PD target engagement in healthy volunteers. This de-risks the path toward Phase 2 initiation in dermatologic/GI indications (2027). Near-term catalyst: TTI-101 Phase 1b/2 HCC topline data in 2H 2026. Key risk: company requires additional funding to initiate new trials beyond current cash runway (Q4 2026).
Price Chart
Executive Summary
Tvardi Therapeutics disclosed Phase 1 results for its next-generation STAT3 inhibitor, TTI-109, a phosphate prodrug of TTI-101. The study confirmed rapid prodrug conversion with equivalent active-moiety exposure at molar-equivalent doses, improved GI tolerability (mean diarrhea duration 0.46 days vs 3.35 days for TTI-101), and pharmacodynamic evidence of target engagement with reductions of up to 60% in STAT3-driven Th17, Tfh, and B cell populations in healthy volunteers. The company plans to advance TTI-109 into dermatologic and GI indications, pending IND clearance and additional funding, with topline Phase 1b/2 HCC data for TTI-101 expected in 2H 2026.
Key Facts
- TTI-109 is a phosphate prodrug of TTI-101 that rapidly converts to active TTI-101 within 2 hours, producing nearly identical plasma levels at molar-equivalent doses.
- 21-day repeat dosing showed stable, dose-proportional PK with TTI-101 concentrations above the STAT3 IC50, and similar PK at Day 1 and 21.
- Pharmacodynamic data showed placebo-adjusted reductions of up to 60% across STAT3-driven immune cell populations including Th17, Tfh, and B cell subsets in the MAD cohort.
- At near-equivalent doses, mean diarrhea duration for TTI-109 500 mg BID was 0.47 days vs 3.35 days for TTI-101 400 mg BID, comparable to placebo at 1.19 days.
- No serious adverse events, no dose-dependent TEAE pattern, and no clinically relevant changes in vital signs or ECGs were observed.
- In the SAD study, exposures remained above the STAT3 IC50 at doses from 250 mg to 1000 mg; in MAD, exposures were sustained above IC50 at BID doses from 125 mg to 500 mg.
- Cash and short-term investments of $25.0M as of March 31, 2026, expected to fund operations into Q4 2026.
- Topline data from the ongoing Phase 1b/2 REVERT Liver Cancer trial of TTI-101 in HCC is expected in 2H 2026.
- Company plans to initiate TTI-109 studies in dermatology/GI in 2027, subject to IND clearance and additional funding.
Financial Impact
Clinical-stage biotech: no revenue reported; cash runway through Q4 2026 with $25.0M; Phase 1b/2 HCC topline catalyst expected 2H 2026.
Risk Factors
- Cash runway only to Q4 2026; additional capital required to fund TTI-109 Phase 2 trials.
- Tvardi's ability to initiate dermatologic/GI programs is subject to IND clearance and additional funding.
- Phase 1b/2 HCC topline data is preliminary with small sample sizes (n=21 for Cohort C, n=8 for B, n=12 for A) as of Aug 2024; cross-study comparisons are not robust.
- Forward-looking statements regarding development timelines and potential advantages over competitors remain unvalidated.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001104659-26-080930 |
| Document: tm2619879d1_8k.htm | 0001104659-26-080930 |
| Document: tm2619879d1_ex99-1.htm | 0001104659-26-080930 |
| Document: 0001104659-26-080930-index-headers.html | 0001104659-26-080930 |
| Document: 0001104659-26-080930-index.html | 0001104659-26-080930 |
| Document: 0001104659-26-080930.txt | 0001104659-26-080930 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 21, 2026 9w ago | Institutional Cluster | $1.86 $1.61 | ▲ +13.44% | ▲ +12.91% | $0.8651 (+53.49%) |
Aug 14, 2026 10w ago | 8-K | $1.90 $1.83 | ▼ −3.68% | ▼ −1.69% | $0.8651 (−54.47%) |
Aug 14, 2026 10w ago | Press Release | $1.90 $1.83 | ▼ −3.68% | ▼ −1.69% | $0.8651 (−54.47%) |
Jul 30, 2026 12w ago | 8-K | $2.10 $1.80 | ▼ −14.29% | ▼ −18.25% | $0.8651 (−58.80%) |
Jul 7, 2026 16w ago | 8-K | $3.10 $2.02 | ▼ −34.84% | ▼ −36.17% | $0.8651 (−72.09%) |
May 14, 2026 23w ago | EFFECT | $3.96 $2.64 | ▲ +33.33% | ▲ +32.48% | $0.8651 (+78.15%) |
May 13, 2026 23w ago | EFFECT | $3.95 $2.71 | ▲ +31.39% | ▲ +30.78% | $0.8651 (+78.10%) |
May 8, 2026 24w ago | Press Release | $4.18 $2.89 | ▼ −30.86% | ▼ −30.88% | $0.8651 (−79.30%) |
Apr 23, 2026 26w ago | DEFA14A | $3.10 $3.59 | ▲ +15.81% | ▲ +11.78% | $0.8651 (−72.09%) |
Mar 31, 2026 29w ago | 8-K | $3.00 $3.06 | ▲ +2.00% | ▼ −7.72% | $0.8651 (−71.16%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers